I think I’m worth it, why doesn’t NICE?BMJ 2008; 337 doi: http://dx.doi.org/10.1136/bmj.a1717 (Published 17 September 2008) Cite this as: BMJ 2008;337:a1717
- Bruna Carnevale, general practitioner, London
Recent media coverage of decisions of the National Institute for Health and Clinical Evidence (NICE) not to make certain drugs available on the NHS has been very poignant for me. Going through the ups and downs of metastatic renal cancer can’t help but induce my passionate response to NICE’s interim ruling on the drugs relevant to my condition—and indeed that I take. These drugs are sunitinib, sorafenib, and bevacizumab, all of which are licensed and have proved to be of benefit, increasing survival in an area of illness with very few options and where the …
Log in using your username and password
Log in through your institution
Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial